Examkin

Soru

Zorluk: OrtaMonitoring and Treatment Evaluation

A 6262-year-old man presents to the outpatient clinic for a follow-up visit. Three days ago, he was evaluated in the emergency department for right calf pain and swelling. A venous compression ultrasound confirmed an acute, unprovoked deep vein thrombosis in the right popliteal vein. He was started on oral apixaban monotherapy and discharged. He has a history of essential hypertension and osteoarthritis. His current medications include apixaban, lisinopril, and acetaminophen. He feels well today, and his right leg swelling has mildly improved. His blood pressure is 128/78128/78 mmHg, heart rate is 7272/min, and respiratory rate is 1414/min. Which of the following parameters are strictly recommended to obtain at baseline and for periodic monitoring during this patient's ongoing anticoagulant therapy? (Select all that apply)

  1. Serum creatinineCevap
  2. Complete blood countCevap
  3. C
    Prothrombin time and activated partial thromboplastin time
  4. D
    Serial D-dimer measurements
  5. E
    Serial lower extremity venous compression ultrasonography

Cevap

The correct parameters to monitor are serum creatinine and a complete blood count.
Direct oral anticoagulants (DOACs), including the factor Xa inhibitor apixaban, have predictable pharmacokinetics and do not require routine therapeutic drug monitoring. However, because apixaban is partially cleared by the kidneys, baseline and periodic monitoring of serum creatinine is essential to identify renal impairment, which would necessitate dose adjustment or discontinuation to prevent drug accumulation and bleeding. Additionally, a baseline complete blood count is required to ensure adequate initial platelet counts and to establish a baseline hemoglobin level. Periodic monitoring of the complete blood count is necessary to detect occult bleeding, the most common serious adverse effect of anticoagulant therapy.

Adım Adım Çözüm

1
Identify the clinical scenario
A patient with an acute, unprovoked deep vein thrombosis recently started on apixaban, a direct oral anticoagulant (DOAC).
Understanding the specific medication class dictates the monitoring requirements.
2
Determine the monitoring requirements for DOAC therapy
Unlike warfarin, DOACs do not require routine therapeutic monitoring of coagulation pathways such as PT/INR or aPTT.
DOACs have predictable pharmacokinetics and a wide therapeutic index.
3
Identify baseline and periodic safety monitoring needs
DOACs require baseline and periodic assessment of renal function (serum creatinine) and a complete blood count.
Renal function must be monitored for proper dosing, and a complete blood count is necessary to detect occult bleeding.

Anahtar Kavram

Direct oral anticoagulants (DOACs) require baseline and periodic monitoring of renal function and complete blood count, but do not require routine coagulation cascade monitoring (PT/aPTT) or serial imaging if symptoms are resolving.
Tahmini Süre:1m 30s
Bu soruyu puanla

Konular

Monitoring and Treatment Evaluation

Bu konudan daha fazla soru